News
WVE
2.820
+17.50%
0.420
Insiders Buy More Than $21M Of 3 Penny Stocks
U.S. stocks traded slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested ...
Benzinga · 3d ago
MFGP, OMER and ZYXI among mid-day movers
Gainers: Ocean Bio-Chem (OBCI) +117%. Exela Technologies (XELA) +47%. Boxed (BOXD) +44%. Revlon (REV) +39%. Vivakor (VIVK) +22%. Omeros Corporation (OMER) +21%. Vor Biopharma (VOR) +21%. Wave Life Sciences (WVE)
Seekingalpha · 3d ago
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday.
Benzinga · 3d ago
40 Stocks Moving In Wednesday's Mid-Day Session
 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Benzinga · 3d ago
22nd Century, Wave Life top healthcare gainers; while Athira, Neptune Wellness lead losers' pack
Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences (WVE) +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma (ATHA) -70%. Neptune Wellness Solutions (NEPT) -32%. 4D pharma (LBPS) -...
Seekingalpha · 3d ago
U.S. Markets Open Lower; Winnebago Posts Upbeat Results
U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Wednesday.
Benzinga · 3d ago
Ra Capital Management raises passive stake in Wave Life Sciences
Wave Life Sciences (NASDAQ:WVE) has disclosed a share purchase by 10% owner Ra Capital Management. Ra Capital Management bought over 9.48M shares of the company's ordinary shares at $2.15 in
Seekingalpha · 3d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 3d ago
Here's What Wave Life Sciences Ltd.'s (NASDAQ:WVE) Shareholder Ownership Structure Looks Like
If you want to know who really controls Wave Life Sciences Ltd. ( NASDAQ:WVE ), then you'll have to look at the makeup...
Simply Wall St. · 5d ago
WAVE Life Sciences's Return On Capital Employed Insights
WAVE Life Sciences (NASDAQ:WVE) brought in sales totaling $1.75 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 8.71%, resulting in a loss of $37.81 million.
Benzinga · 06/17 15:04
Wave Life Sciences to raise $70M in stock offering
Wave Life Sciences (NASDAQ:WVE) priced an underwritten offering of 25.5M shares at an offering price of $2.15/share and to RA Capital Management, in lieu of ordinary shares, pre-funded warrants to purchase
Seekingalpha · 06/14 13:14
BRIEF-Wave Life Sciences Announces Pricing Of $70.0 Million Underwritten Offering
reuters.com · 06/14 13:03
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of ...
GlobeNewswire · 06/14 13:00
Wave Life Sciences Prices $70 Million Underwritten Offering
MT Newswires · 06/14 10:18
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/06 09:31
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno,...
GlobeNewswire · 05/25 12:30
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 05/23 16:12
Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences
RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental. 
Benzinga · 05/13 18:51
Wave Life Sciences slips as H.C. Wainwright lowers target
Then shares of Wave Life Sciences (NASDAQ:WVE) are trading lower in the morning hours Friday after H.C. Wainwright trimmed the price target of the clinical-stage genetic medicine company citing a
Seekingalpha · 05/13 14:18
Inotiv, TScan Therapeutics top healthcare gainers; Opiant, Renovacor lead losers' pack
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. PetIQ (PETQ) ...
Seekingalpha · 05/13 14:07
More
Webull provides a variety of real-time WVE stock news. You can receive the latest news about Wave Life Scienc through multiple platforms. This information may help you make smarter investment decisions.
About WVE
Wave Life Sciences Ltd. is a Singapore-based clinical-stage genetic medicines company engaged in delivering life-changing treatments for people battling devastating diseases. It is engaged in developing oligonucleotides that target ribonucleic acid (RNA) and harness existing cellular machinery to reduce the expression of disease-promoting RNA or proteins, restore the production of functional proteins, or modulate protein expression. Its lead clinical development programs are designed to treat genetic diseases within the central nervous system (CNS), including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington’s disease (HD), and muscular dystrophies, including Duchenne muscular dystrophy (DMD). Its programs include WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated ALS and FTD, WVE-003 (silencing), its mHTT SNP3 molecule for the treatment of HD, and WVE-N531 (splicing), its exon 53 molecule for the treatment of DMD.